2
RUDN researchers test a new TB vaccine

RUDN researchers test a new TB vaccine

A clinical pharmacologist from RUDN University together with his colleagues from Gamaleya Research Institute of Epidemiology and Microbiology completed the second stage of a clinical trial of a new TB vaccine that was conducted with the participation of 180 volunteers. The trial confirmed the safety and efficiency of the vaccine.

Every year, Mycobacterium tuberculosis infects 10 mln and kills 1.4 mln people which makes prevention and treatment of tuberculosis one of the priority goals of the World Health Organization. Currently, the main weapon against tuberculosis is the BCG vaccine that prevents tuberculous meningitis and miliary tuberculosis. However, it is still unable to protect us from all forms of the disease. Moreover, for unknown reasons, it can be less effective in some populations than in others. A medic from RUDN University together with his colleagues conducted a clinical trial of a new TB vaccine that is supposed to enhance the immunity acquired after BCG vaccination.

“GamTBvac is a TB vaccine that contains three antigene fragments of Mycobacterium tuberculosis. It is these elements that our immune system is expected to react to in order to develop immunity. For better stability, the fragments are bound with a dextran-binding domain—a fragment of proteins taken from the bacterium Leuconostoc mesenteroides. The vaccine also contains an adjuvant, that is, an additional substance that enhances the immune response. The adjuvant contains dextran, diethylaminoethyl dextran, and oligodeoxynucleotides,” said Prof. Sergey Fitilev, MD, from the Department of General and Clinical Pharmacology, RUDN University.

In total, there are 14 alternative vaccines in development in the world that could act independently or in combination with the BCG vaccine. Among them are weakened strains of human or bovine tuberculosis bacillus, DNA vaccines and recombinant subunit vaccines. The GamTBvac that the RUDN medic experienced belongs to the latter type. Previously, doctors on 60 volunteers have already demonstrated the safety of this drug and have shown that half the dosage causes a high and stable immune response and is easily tolerated by patients. The second phase of clinical trials consists of double-blind randomized placebo-controlled trials on 180 participants. All participants had previously received the BCG vaccine.

The volunteers were twice injected with 0.5 ml of the vaccine or placebo subcutaneously with an interval of eight weeks. The double-blind type of study means that until the end of the trial, neither patients nor doctors know who got into the vaccine group and who received a placebo. This avoids subjective interpretations of the result. After vaccination, doctors took a blood test from patients eight times and studied their immune response between the 14th and 150th day after vaccination. The level of gamma interferon immune proteins turned out to be maximum on day 21, and by day 150 it was twice the level before vaccination. The level of antibodies in patients increased by 78 days after vaccination. 94%-98% had an immune response to fragments of Mycobacterium tuberculosis bacillus. Although the results do not yet show whether this is enough to protect against the disease, they will be the basis for further testing.

The results of the study were published in Vaccines.

International scientific cooperation View all
03 Nov 2017
The main goal of the RUDN University and UNISDR Office for Northeast Asia and Global Education and Training Institute for Disaster Risk Reduction at Incheon (UNISDR ONEA-GETI) cooperation is to obtain knowledge about disaster risk reduction and international experience in this area for creating training courses for basic and additional professional education in RUDN
1537
Student's Scientific Initiatives View all
03 Nov 2017
June 22 - 26, 2017 in Barnaul, Altai State University, took place the Summer Academy of the BRICS Youth Assembly, an international event that brought together representatives of different countries
1618
Similar newsletter View all
19 Apr
A huge pizza and a jug of water, why should 5G networks be sliced? The winners of RUDN science competition explain

RUDN summarized the results of the scientific competition "Project Start: work of the science club ". Students of the Faculty of Physics, Mathematics and Natural Sciences have created a project for a managed queuing system using a neural network to redistribute resources between 5G segments. How to increase flexibility, make the network fast and inexpensive and reach more users — tell Gebrial Ibram Esam Zekri ("Fundamental Computer Science and Information Technology", Master's degree, II course) and Ksenia Leontieva ("Applied Mathematics and Computer Science", Master's degree, I course).

72
19 Apr
Lyricists and physicists are now on equal terms: the first humanitarian laboratory opened in RUDN

What is your first association with the word “laboratory”? Flasks and beakers? Microscopes and centrifuges? Yes, many of us would answer the same way.

94
19 Apr
The National Demographic Report 2023 was published with the participation of RUDN. Demographic well-being of Russian regions

The National Demographic Report, 2023 Demographic Well-Being of Russian Regions (hereinafter - the National Demographic Report) was prepared by the scientific team of the Institute of Demographic Studies of the Federal Research Center of the Russian Academy of Sciences, the Vologda Scientific Center of the Russian Academy of Sciences, Peoples' Friendship University of Russia, the Center for Family and Demography of the Academy of Sciences of the Republic of Tatarstan, as well as with the participation of leading scientists from the Republic of Bashkortostan, Stavropol Krai, Volgograd, Ivanovo, Kaliningrad, Nizhny Novgorod, Sverdlovsk Oblasts and Khanty-Mansi Autonomous Okrug–Yugra.

72
Similar newsletter View all